Today: 7 February 2026
Subscribe
Browse Category

Pharma News News 9 December 2025 - 16 December 2025

Johnson & Johnson Stock After Hours (Dec. 15, 2025): JNJ Rises on FDA Priority Voucher — What to Know Before Tuesday’s Open

Johnson & Johnson Stock After Hours (Dec. 15, 2025): JNJ Rises on FDA Priority Voucher — What to Know Before Tuesday’s Open

Johnson & Johnson (NYSE: JNJ) shares finished Monday, December 15, 2025 higher and held modest gains in extended trading — a notable showing for a defensive blue chip as investors brace for a data-heavy week and shifting rate expectations. JNJ closed at $214.17 (+1.22%) and traded around $214.99 in after-hours (+0.38%) as of 7:15 p.m. ET. During the regular session, the stock moved between $209.01 and $215.19 on roughly 8.4 million shares. StockAnalysis+1 In the broader market, U.S. stocks ended slightly lower on Monday as investors positioned for major economic releases later this week. TradingView What moved Johnson & Johnson
16 December 2025
·····
Amicus Therapeutics (FOLD) Stock News Today: DMX-200 Trial Milestone, 52-Week High Momentum, and Analyst Forecasts (Dec. 15, 2025)

Amicus Therapeutics (FOLD) Stock News Today: DMX-200 Trial Milestone, 52-Week High Momentum, and Analyst Forecasts (Dec. 15, 2025)

Amicus Therapeutics, Inc. (Nasdaq: FOLD) is back on investors’ radar as the rare-disease biotech extends a strong 2025 run—helped by a milestone quarter of GAAP profitability, expanding global launches for its Pompe franchise, and fresh news tied to a Phase 3 kidney-disease program it licensed earlier this year. On Monday, December 15, 2025, Amicus shares traded around $10.93 intraday after opening near $10.55, with the session range pushing into the low $11 area. Below is a detailed look at the latest Amicus Therapeutics stock news, what Wall Street is forecasting, and the key catalysts (and risks) investors are weighing as
15 December 2025
···
GSK plc Stock News & Forecasts (Dec. 15, 2025): FDA Catalyst for Depemokimab, EU Backs Nucala and Arexvy, Analysts Map the Path Ahead

GSK plc Stock News & Forecasts (Dec. 15, 2025): FDA Catalyst for Depemokimab, EU Backs Nucala and Arexvy, Analysts Map the Path Ahead

GSK plc Stock News & Forecasts (Dec. 15, 2025): FDA Catalyst for Depemokimab, EU Backs Nucala and Arexvy, Analysts Map the Path Ahead GSK plc stock (LSE: GSK, NYSE: GSK) is ending 2025 with a rare “cluster” of market-moving catalysts packed into the same two-week window: fresh U.S. regulatory momentum for a new antibiotic, European regulatory backing for multiple respiratory products, and an imminent FDA decision that could reshape GSK’s long-term outlook in severe asthma and nasal polyps. For investors, this isn’t just headline noise. It’s the kind of sequencing—approval decisions, label expansions, and portfolio reinforcement—that can change how analysts
15 December 2025
·····
Corona Remedies Share Price Today (15 Dec 2025): Pharma Stock Debuts at 38% Premium After ₹655-Crore IPO — Latest News, Forecasts, Valuation and Analyst Views

Corona Remedies Share Price Today (15 Dec 2025): Pharma Stock Debuts at 38% Premium After ₹655-Crore IPO — Latest News, Forecasts, Valuation and Analyst Views

New Delhi / Mumbai, December 15, 2025 — Corona Remedies Limited, the Ahmedabad-headquartered branded pharmaceutical formulations company (not the beer), hit Dalal Street with a headline-worthy debut on Monday: the stock listed at a 38%+ premium to its IPO price, quickly becoming one of the most-watched new names in India’s healthcare space. Business Standard+2Moneycontrol+2 Below is a consolidated, publication-ready roundup of today’s key developments (15.12.2025) — including the latest price action, what the grey market had predicted, and how brokerages and IPO research notes are framing Corona Remedies’ valuation and outlook. Corona Remedies stock news today: listing pop, intraday surge
15 December 2025
·····
Merck stock (MRK): News, dividend date, Keytruda updates and analyst forecasts to watch before the U.S. market opens Dec. 15, 2025

Merck stock (MRK): News, dividend date, Keytruda updates and analyst forecasts to watch before the U.S. market opens Dec. 15, 2025

Merck & Co., Inc. (NYSE: MRK) heads into Monday’s U.S. session (December 15, 2025) with investors juggling a mix of near-term headlines and long-term franchise questions: a fresh dividend “reset” that makes Dec. 15 an important calendar day, ongoing scrutiny around RSV prevention products, and high-stakes execution on the company’s plan to diversify beyond Keytruda ahead of the drug’s expected loss of exclusivity later this decade. MarketWatch+2Reuters+2 Below is what to know before the opening bell. MRK stock: where shares stand heading into Monday Merck shares most recently closed at $100.30 on Friday, Dec. 12, extending a three-day winning streak
14 December 2025
·····
Altimmune (ALT) Stock News, Forecasts and Analysis for Dec. 12, 2025: What Investors Are Watching Ahead of Pemvidutide Catalysts

Altimmune (ALT) Stock News, Forecasts and Analysis for Dec. 12, 2025: What Investors Are Watching Ahead of Pemvidutide Catalysts

Altimmune, Inc. (NASDAQ: ALT) is back on many biotech watchlists as investors weigh two competing forces: a near-term clinical and regulatory catalyst calendar for pemvidutide (the company’s lead asset) and a capital-raising backdrop that can quickly change the stock’s risk/reward profile. On Friday, Dec. 12, 2025 , ALT shares are trading in a volatility-heavy tape where options flow, analyst targets, and impending data readouts are all influencing sentiment. Below is a detailed, publication-ready look at today’s ALT stock action , the latest company and clinical news , Wall Street forecasts , and the key catalysts and risks that matter most
12 December 2025
·····
Bristol-Myers Squibb Stock (BMY) News, Forecasts and Analysis for Dec. 12, 2025: Dividend Hike, FDA Updates, and Wall Street’s 2026 Focus

Bristol-Myers Squibb Stock (BMY) News, Forecasts and Analysis for Dec. 12, 2025: Dividend Hike, FDA Updates, and Wall Street’s 2026 Focus

Dec. 12, 2025 — Bristol-Myers Squibb Company (NYSE: BMY ) is back in the spotlight heading into year-end as investors weigh a fresh dividend increase, meaningful regulatory milestones in oncology, and a pipeline that has delivered both high-profile wins and frustrating setbacks in 2025. By mid-day Friday, BMY stock traded around $52.50, up roughly 2.5% , reflecting a market that’s starting to re-price near-term catalysts even as longer-term questions—patent cliffs, trial readouts, and litigation—remain front and center. BMY stock price today: what’s moving the shares on Dec. 12 The most immediate “today” driver is Wall Street sentiment . On Friday,
12 December 2025
·····
Rhythm Pharmaceuticals (RYTM) Hits Record High on Rare-Disease Breakthrough: Latest News, Stock Forecast and Analyst Outlook

Rhythm Pharmaceuticals (RYTM) Hits Record High on Rare-Disease Breakthrough: Latest News, Stock Forecast and Analyst Outlook

Rhythm Pharmaceuticals, Inc. (NASDAQ: RYTM) stock is on a tear. On 11 December 2025, shares surged to a new all‑time high after the company reported encouraging mid‑stage data in Prader‑Willi syndrome (PWS) and investors refocused on a growing obesity franchise built around its melanocortin‑4 receptor (MC4R) agonist, IMCIVREE (setmelanotide).Investing.com+1 As of Thursday morning, RYTM was trading around $121 per share, up more than 15% on the day according to real‑time data from MarketBeat, and roughly 80–90% higher year‑to‑date.MarketBeat+2Investing.com+2 For a mid‑cap biotech that is still loss‑making, that kind of move demands a closer look at what changed, what analysts expect
11 December 2025
····
Eli Lilly (LLY) After Hours: How a $6 Billion Bet, Fresh Oncology Data and Fed Rate Cut Set the Stage for December 11, 2025

Eli Lilly (LLY) After Hours: How a $6 Billion Bet, Fresh Oncology Data and Fed Rate Cut Set the Stage for December 11, 2025

Eli Lilly and Company (NYSE: LLY) closed just under the psychologically important $1,000 mark on Wednesday, December 10, 2025, then ticked slightly higher in after‑hours trading as investors digested a wave of company‑specific news against a backdrop of a fresh Federal Reserve rate cut.Yahoo Finance+1 Below is what happened after the bell on Dec. 10 and what traders and long‑term investors should know before the market opens on Dec. 11, 2025. LLY Stock After the Bell: Price Action at a Glance That’s the price backdrop. The real story, however, is today’s news flow—and there was a lot of it. Today’s
11 December 2025
····
Ascendis Pharma (ASND) Stock Slides After Q3 Miss and FDA Delay – What Investors Need to Know on December 9, 2025

Ascendis Pharma (ASND) Stock Slides After Q3 Miss and FDA Delay – What Investors Need to Know on December 9, 2025

Ascendis Pharma A/S (NASDAQ: ASND) is back in the spotlight on December 9, 2025, after its share price slipped again while Wall Street continues to project hefty upside and label the name a “Buy” or “Strong Buy.” The Danish biotech, known for its TransCon long-acting prodrug platform and endocrine rare disease franchise, is wrestling with three forces at once: Let’s unpack what’s going on with Ascendis Pharma stock today, how the story changed in recent weeks, and what current forecasts say about where ASND could go next. ASND stock today: price action and context By late trading on December 9,
9 December 2025
·····
Eli Lilly (LLY) Stock on December 9, 2025: Jaypirca Breakthrough, Adverum Deal and Zepbound Price Cuts Reframe the Outlook

Eli Lilly (LLY) Stock on December 9, 2025: Jaypirca Breakthrough, Adverum Deal and Zepbound Price Cuts Reframe the Outlook

Eli Lilly and Company (NYSE: LLY) is once again in the spotlight. As of early trading on December 9, 2025, Eli Lilly stock is hovering around $997 per share, roughly 10% below its late‑November all‑time high but still up about 30% year to date and about 25% over the past 12 months.FinanceCharts Today’s story is about more than the share price: fresh Phase 3 cancer data for Jaypirca, the completed acquisition of Adverum, a higher 2026 dividend, Nobel laureate Carolyn Bertozzi rejoining the board, and an ongoing price reset for blockbuster obesity drug Zepbound. Together they reshape how investors are
9 December 2025
····
(OCUL) Stock Soars on Accelerated Wet AMD NDA – Price, Forecast & Risk Analysis as of December 9, 2025

(OCUL) Stock Soars on Accelerated Wet AMD NDA – Price, Forecast & Risk Analysis as of December 9, 2025

All figures and opinions reflect information available on December 9, 2025 and may change over time. This article is for informational purposes only and is not investment advice. OCUL Stock Today: A 52‑Week High After a Single Press Release Ocular Therapeutix, Inc. (NASDAQ: OCUL) has suddenly moved from sleepy mid-cap biotech to front-page ticker. On Monday, December 8, the stock closed at $16.11, up 28.1% on the day, after trading as high as $16.44 and setting a new 52‑week high. The prior close was $12.58, meaning the name has rallied sharply over just a few sessions.FinancialContent+1 Year to date, OCUL
9 December 2025
····
1 … 4 5 6 7 8 … 11

Stock Market Today

ST Engineering stock price drops 2% to S$9.71 as drone-autonomy tie-up grabs attention

ST Engineering stock price drops 2% to S$9.71 as drone-autonomy tie-up grabs attention

7 February 2026
ST Engineering shares fell 1.9% to S$9.71 Friday, outpacing the Singapore market’s 0.8% drop amid a tech-led selloff. The company signed a deal with Shield AI at the Singapore Airshow to integrate autonomy software into its unmanned platforms and unveiled a small drone capable of carrying explosives. About 6.9 million shares traded as investors await full-year results on Feb. 27.
Go toTop